Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells
- 1 November 1991
- journal article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 33 (6) , 395-397
- https://doi.org/10.1007/bf01741600
Abstract
The activity of lymphokine-activated killer (LAK) cells is supported by various cytokines. The objective of this study was to see if recombinant interleukin-6 (IL-6) either alone or in combination with interleukin-2 (IL-2) has any effect on the generation of LAK cells. Peripheral blood mononuclear cells of healthy donors were cultured for 4 or 6 days with both cytokines either alone or in combination. LAK activity against K562 and natural killer-resistant Daudi cells was assessed by a 4-h and an 18-h51Cr-release assay at various effector to target ratios. IL-6 alone in increasing concentrations did not induce LAK cell activity. Neither additive nor synergistic effects of IL-6 with IL-2 were observed. Immunofluorescence analysis with phycoerythrin-conjugated anti-CD56 antibody demonstrated that IL-6 could not maintain or increase the number of CD56-positive cells over a 6-day culture period. These results suggest that IL-6 does not support LAK cell generation by itself or increase LAK cell activity in combination with IL-2.Keywords
This publication has 17 references indexed in Scilit:
- An explanation of the variable clinical response to interleukin 2 and LAK cellsImmunology Today, 1990
- Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.The Journal of Experimental Medicine, 1990
- Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity.The Journal of Experimental Medicine, 1989
- Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patientsCancer Immunology, Immunotherapy, 1989
- The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation.The Journal of Immunology, 1988
- Production of hybridoma growth factor by human monocytesEuropean Journal of Immunology, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- The use of 51Cr release as a measure of lymphocyte-mediated cytolysis in vitroCellular Immunology, 1973